Tumor vaccines for treating glioma and solid tumors
Official title: Preclinical and Clinical Research on Therapeutic Vaccines for Solid Tumors
Run by Huashan Hospital · NCT06102837 · Data updated 2026-11-12
This study is testing whether a new type of vaccine made from immune cells can help people with brain tumors live longer and feel better.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 340 (estimated) |
| Sponsor | Huashan Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | October 2023 |
| Main results expected | October 2027 |
| Study ends | October 2027 |
| Registry record updated | October 26, 2023 |
| Trial ID | NCT06102837 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include glioma patients or non-tumor patients with specific neurological conditions who can provide tissue samples for analysis.
✕Probably not a fit
Patients currently participating in other clinical trials or pregnant women may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on glioma, a type of brain tumor with limited treatment options and poor prognosis. It aims to evaluate the effectiveness of dendritic cell (DC) vaccines in improving patient outcomes, particularly in extending overall survival for those with newly diagnosed and recurrent glioblastoma. The study will involve patients from the Department of Neurosurgery at Huashan Hospital, who will provide tissue samples for analysis. The research leverages advancements in immunotherapy and aims to contribute to the development of new treatment strategies for solid tumors.
Why it matters
Potential benefit: If successful, this study could provide a new immunotherapy option that significantly improves survival rates for glioma patients.
How similar studies have gone: Previous clinical trials have shown that tumor vaccines can improve the prognosis of glioma patients, indicating a promising approach in this area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: The patients with glioma patients/non-tumor patients (hemorrhagic stroke, ischemic stroke, and traumatic brain injury) in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled: 1. They were no age limit, male and female; 2. The pathological results of frozen section during operation were gliomas or non-tumor; 3. Tissue (6 mm \* 6 mm) can be used for cell sorting on the basis of not affecting clinical routine diagnosis; 4. Sign informed consent. Exclusion Criteria: Patients who meet any of the following criteria will not be included in this study: 1. Participants in other clinical trials; 2. Pregnant women.
Where it's running
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
-
SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1
This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.
-
FAPI PET imaging with FAPI-RuiJ and FAPI-04 in solid tumors
This study tests two FAP-targeted PET tracers (FAPI-RuiJ and FAPI-04) to see which better detects, stages, and monitors solid tumors.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.